Revised SPC: Vyndaqel (tafamidis meglumine) 20 mg soft capsules

SPC has been updated to reflect the new Pfizer Marketing Authorisation for 61mg formulation, which is bioequivalent to 80 mg tafamidis meglumine dose administered as four 20 mg capsules, and was developed for patient convenience to enable a single capsule for daily administration


electronic Medicines compendium